肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法

2021-01-08 Allan MedSci原创

ROR1CAR-TCAR-NK酪氨酸激酶样孤儿受体1（ROR1）
关注

生物制药公司Oncternal Therapeutics今天宣布，它与瑞典卡罗林斯卡研究所建立了研发合作关系，以推进靶向ROR1的CAR-T细胞和CAR-NK细胞疗法。

生物制药公司Oncternal Therapeutics今天宣布，它与瑞典卡罗林斯卡研究所建立了研发合作关系，以推进靶向ROR1的CAR-T细胞和CAR-NK细胞疗法。

卡罗林斯卡研究所NextGenNK中心的Hans-Gustaf Ljunggren博士说：“鉴于NK细胞是在卡罗林斯卡研究所发现的，我们很高兴与行业合作伙伴一起将科学进步转化为有益于癌症患者的下一代细胞疗法。我们期待与Oncternal合作，开发针对ROR1的T细胞和NK细胞疗法，ROR1是许多肿瘤学适应症的有效靶标”

Oncternal总裁兼首席执行官James Breitmeyer博士说：“我们很荣幸与世界领先的学术团队合作，以加快靶向ROR1的细胞免疫疗法的开发。ROR1已成为癌症治疗的一个重要且尚未开发的靶标，我们相信靶向ROR1的CAR-T和CAR-NK治疗对于血液系统癌症和实体瘤患者均具有重大前景”。

ROR1被认为是个非常有潜力的靶点，因为它位于细胞表面，更重要的是，它在肿瘤细胞中高度表达，而在成人健康组织中的表达量很低。

 

原始出处：

https://www.firstwordpharma.com/node/1789563?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-12-18 仁者大医

    #CAR-#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-06-17 般若傻瓜

    #eRNA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-06-13 ms24272190615788285182

    #Therapeutic#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-08-17 feather89

    #PE#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-06-04 nian.wang1982

    #研究所#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-07-11 124988c7m106暂无昵称

    #ERA#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-04-08 yulin2006

    #卡罗林斯卡#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-10 zhaojie88

    #therapeutics#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-10 feather83

    #NK细胞疗法#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1781402, encodeId=74fe1e8140256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4059, encryptionId=8ce8405907, topicName=CAR-)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 18 17:54:37 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008779, encodeId=59ba2008e7949, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Thu Jun 17 01:54:37 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974397, encodeId=782219e4397c2, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Jun 13 20:54:37 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728766, encodeId=60461e28766c4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 17 02:54:37 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801075, encodeId=4b4718010e56c, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Fri Jun 04 16:54:37 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739032, encodeId=043d1e390321c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Sun Jul 11 03:54:37 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027689, encodeId=70e7202e6896c, content=<a href='/topic/show?id=c26836533f3' target=_blank style='color:#2F92EE;'>#卡罗林斯卡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36533, encryptionId=c26836533f3, topicName=卡罗林斯卡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Thu Apr 08 20:54:37 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350847, encodeId=13fa135084ef2, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12853, encryptionId=93a11285330, topicName=NK细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e9715863942, createdName=feather83, createdTime=Sun Jan 10 11:54:37 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914979, encodeId=97409149e90e, content=<a href='/topic/show?id=5b4640e04a' target=_blank style='color:#2F92EE;'>#CAR-T疗法#</a>&<a href='/topic/show?id=50d0103e271c' target=_blank style='color:#2F92EE;'>#CAR-NK细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4070, encryptionId=5b4640e04a, topicName=CAR-T疗法), TopicDto(id=103727, encryptionId=50d0103e271c, topicName=CAR-NK细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sat Jan 09 20:23:47 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-09 zb1235672

    #CAR-T疗法#&#CAR-NK细胞治疗#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Blood：在慢性淋巴细胞白血病中，Wnt5a诱导ROR1招募DOCK2激活Rac1/2，从而增强CLL细胞增殖

中心点：Wnt5a可通过诱导ROR1与DOCK2互作增强Rac1/2的激活。ROR1-DOCK2互作有助于Wnt5a增强的CLL细胞增殖。摘要：酪氨酸激酶样孤儿受体1（ROR1）是表达在慢性淋巴细胞白血病（CLL）细胞上的一种癌胚蛋白，可作为Wnt5a的受体，促进白血病细胞迁移、增殖和存活。研究人员发现Wnt5a可诱导ROR1与DOCK2形成复合物，从而诱导激活Rac1/2；这一效应可可被cirm

CLIN CANCER RES：人肿瘤及正常组织ROR1蛋白表达分析

一般认为ROR1为肿瘤特异性表达的蛋白，这使得ROR1成为肿瘤治疗的理想靶点。有许多研究团队正在开发针对ROR1的抗体或CART治疗。之前的一些研究认为ROR1在大部分正在组织中不表达。CLIN CANCER RES近期发表了一篇文章，研究人肿瘤细胞及正常组织表面ROR1表达。

Blood：靶向ROR1递送miR-29b可诱导细胞周期阻滞，有望成为CLL的新疗法

慢性淋巴细胞白血病（CLL）主要由两种形式：侵袭性和惰性。在侵袭性CLL中，低miR-29b表达与不良预后相关。在小鼠B细胞系中过表达miR-29b可引发异常，因此，有必要选择性的将miR-29b引入B-CLL细胞中，以获得治疗效益。癌胚抗原ROR1(受体酪氨酸激酶孤儿受体1)在恶性B-CLL细胞上表达，但不在正常B细胞上表达，提示我们可靶向ROR1来递送治疗性miRs。

PNAS：ROR1与TCL1基因相互作用推动慢性淋巴细胞白血病（CLL）发展

来自加州大学圣地亚哥分校的研究人员报道称，当癌基因ROR1与另外一种癌基因组合到一起时会加速慢性淋巴细胞白血病（CLL）的进程，在小鼠体内促成更快速发展、更具侵袭性的CLL形式。【原文下载】 这些发表在12月30日《美国科学院院刊》（PNAS）上的研究结果表明，ROR1有可能是慢性淋巴细胞白血病的一个重要的治疗靶点。慢性淋巴细胞白血病是最常见的一种血癌形式。在美国慢性

乳腺癌ROR1影响肿瘤细胞的生长和存活

美国加州大学圣迭戈穆尔斯癌症中心的一支科学家团队已鉴定出在只在乳腺癌细胞中表达的一种新蛋白质，这一蛋白质并不在成人正常健康组织中表达。该蛋白质可能为未来癌症治疗的新的靶标，开发出抗癌药物。 在医学博士Thomas J. Kipps，Evelyn和加州大学圣迭戈穆尔斯癌症中心的癌症研究所临时主任Edwin Tasch Chair的带领下，科学家们发现乳腺癌患者的肿瘤细胞通常都表达的受体酪氨酸激

Blood：Cirmtuzumab的抗慢性淋巴细胞白血病机制！

将Nurse样细胞（NLC）与慢性淋巴细胞白血病（CLL）细胞共培养，可诱导白血病细胞的STAT3磷酸化（pSTAT3），该过程可被抗Wnt5a抗体或抗ROR1 mAb cirmtuzumab阻断。研究表明Wnt5a可在30min内诱导NF-κB活化，但需要3个多小时来诱导pSTAT3。

拓展阅读

默克27.5亿美元收购VelosBio，获得靶向ROR1的抗体-药物偶联物（ADC）

1期临床试验结果表明：VLS-101分别让47％的套细胞淋巴瘤患者和80％的弥漫性大B细胞淋巴瘤患者产生应答。